Immediate Impact
1 from Science/Nature 73 standout
Citing Papers
Chemically Modified Platforms for Better RNA Therapeutics
2024 Standout
Cardiovascular Risk Reduction in High-Risk Pediatric Patients: A Scientific Statement From the American Heart Association
2019 Standout
Works of Morris A. Flaum being referenced
A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study.
1992
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Morris A. Flaum | 221 | 50 | 115 | 112 | 9 | 356 | |
| V. Rodriguez | 119 | 111 | 162 | 58 | 18 | 393 | |
| Katiuscia O’Brian | 113 | 39 | 136 | 97 | 13 | 373 | |
| Ka Wah Chan | 174 | 40 | 106 | 25 | 10 | 349 | |
| NH Mulder | 105 | 54 | 135 | 62 | 8 | 402 | |
| J. Marion | 79 | 74 | 105 | 49 | 8 | 336 | |
| P. Fixe | 158 | 36 | 72 | 83 | 12 | 407 | |
| Ellison Rr | 221 | 19 | 100 | 126 | 9 | 313 | |
| JM Rowe | 127 | 52 | 108 | 37 | 11 | 320 | |
| George O. Clifford | 198 | 41 | 60 | 70 | 14 | 345 | |
| Jeremiah Boles | 169 | 45 | 55 | 111 | 11 | 385 |
All Works
Loading papers...